Interaction of vasoactive intestinal peptide with mouse lymphocytes: specific binding and the modulation of mitogen responses
- PMID: 6606671
Interaction of vasoactive intestinal peptide with mouse lymphocytes: specific binding and the modulation of mitogen responses
Abstract
Binding of radioiodinated vasoactive intestinal peptide (VIP) to mouse lymphocytes has been investigated. Specific cell binding of 125I-VIP was demonstrated with lymphocytes from mesenteric lymph nodes, subcutaneous lymph nodes, spleen, and Peyer's patches. The binding of VIP by these cells was accounted for by VIP binding sites upon T cells rather than non-T cells. In the presence of VIP, the in vitro response of lymphocytes to the T cell mitogens concanavalin A (Con A) and phytohemagglutinin (PHA) was inhibited in a dose-dependent fashion, whereas that to the B cell mitogen lipopolysaccharide (LPS) was not. There was a close correlation between the potency of VIP and some structurally related peptides for inhibition of 125I-VIP binding and the effect of those peptides on T cell mitogen responses. These observations demonstrate that mouse T lymphocytes have specific VIP receptors and that VIP can modulate the response of T cells to mitogenic stimulation. VIP may be an important immunoregulatory molecule, and may be implicated in the regulation of T cell function in mucosal tissues innervated by VIP-containing neurons.
Similar articles
-
Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells.Immunology. 1987 Oct;62(2):291-7. Immunology. 1987. PMID: 2960611 Free PMC article.
-
Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen.J Immunol. 1986 Jan;136(1):152-6. J Immunol. 1986. PMID: 2415614
-
Modulation of T lymphocyte proliferation in mice infected with Schistosoma mansoni: VIP suppresses mitogen- and antigen-induced T cell proliferation possibly by inhibiting IL-2 production.Cell Immunol. 1993 Jun;149(1):11-23. doi: 10.1006/cimm.1993.1132. Cell Immunol. 1993. PMID: 8099848
-
Biochemical characteristics of receptors for vasoactive intestinal polypeptide in nervous, endocrine, and immune systems.Fed Proc. 1987 Jan;46(1):192-5. Fed Proc. 1987. PMID: 3026856 Review.
-
Role of vasoactive intestinal peptide in inflammation and autoimmunity.Curr Opin Investig Drugs. 2005 Nov;6(11):1116-23. Curr Opin Investig Drugs. 2005. PMID: 16312132 Review.
Cited by
-
Cloning and expression of the human vasoactive intestinal peptide receptor.Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4986-90. doi: 10.1073/pnas.88.11.4986. Proc Natl Acad Sci U S A. 1991. PMID: 1675791 Free PMC article.
-
Neuroendocrine modulation of the immune system. Possible implications for inflammatory bowel disease.Dig Dis Sci. 1988 Mar;33(3 Suppl):41S-49S. doi: 10.1007/BF01538130. Dig Dis Sci. 1988. PMID: 3278868 Review.
-
Substance P increases lymphocyte traffic and lymph flow through peripheral lymph nodes of sheep.Immunology. 1989 May;67(1):109-14. Immunology. 1989. PMID: 2472354 Free PMC article.
-
Vasoactive intestinal peptide receptor 1 is downregulated during expansion of antigen-specific CD8 T cells following primary and secondary Listeria monocytogenes infections.J Neuroimmunol. 2011 May;234(1-2):40-8. doi: 10.1016/j.jneuroim.2011.02.002. Epub 2011 Mar 10. J Neuroimmunol. 2011. PMID: 21396722 Free PMC article.
-
Unique pattern of cleavage of vasoactive intestinal peptide by human lymphocytes.Immunology. 1989 Apr;66(4):554-8. Immunology. 1989. PMID: 2654011 Free PMC article.